RE: RE: RE: RE: OK, alright... Happy New Year to everyone.
Hopefully 2012 proves to generate some strong and interesting data. My question for you San Fran, is why are you so confident that this drug will work? Many drugs fail phase II and even P III trials.
I read through some of your earlier postings over the past week regarding the statistically significant increases in apoa-1. Interesting data and I agree that there is reasonable evidence to feel confident that statistical increases in circulating apao-1 will be seen. I guess where I get a bit nervous is simply that.... what does a statistically significant 4, 5 or 6% increase in apao-1 mean clinically? I really think this is what most clinicians will be asking.
Why I think that an increase in apoa-1 might be enough to allow a pharma partner to step in and fund phase III, I think more risk for the eventual success or failure of this drug is being pushed into a PIII trial than is typical for other drugs. Of course based on where the share price is right now, just the idea of attracting a pharma partner is enough to move the needle positively.
Of course if there is statistically significant apao-1 increases and positive reductions in plaque remodeling and or composition changes, then this certainly has the potential to be a game changer. 2012 seems to be the make or break year for RVX.
Good luck to all.